Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study

医学 溃疡性结肠炎 安慰剂 内科学 不利影响 临床终点 胃肠病学 临床试验 疾病 病理 替代医学
作者
Baili Chen,Jie Zhong,Xiuling Li,Feng Pan,Yijuan Ding,Yan Zhang,Hong Chen,Fei Liu,Zhenyu Zhang,Ling Zhang,Rafal Drozda,Oleksandr Oliinyk,Aik Han Goh,Xiang Chen,Xiang Sun,David T. Rubin,William J. Sandborn,Minhu Chen
出处
期刊:Gastroenterology [Elsevier BV]
卷期号:163 (6): 1555-1568 被引量:46
标识
DOI:10.1053/j.gastro.2022.08.007
摘要

Current therapies for ulcerative colitis (UC) fail to achieve satisfactory disease control. Selective inhibition of Janus kinase (JAK) type 1 may improve clinical outcomes in patients with UC while avoiding the side effects associated with pan-JAK inhibition. The safety and efficacy of the selective JAK1 inhibitor ivarmacitinib (formerly SHR0302) were evaluated in patients with moderate-to-severe, active UC.AMBER2 was a double-blind, placebo-controlled, phase II trial conducted at 63 clinical centers in China, the United States, and Europe. Patients (N = 164) were randomized 1:1:1:1 to receive oral ivarmacitinib 8 mg once daily (QD), 4 mg twice daily (BID), or 4 mg QD, or placebo for 8 weeks, followed by an 8-week extension period. The primary endpoint was clinical response rate at week 8. Hochberg's procedure was used to control the study-wise type 1 error at alpha=0.1.A total of 146 (89.0%) patients completed 8 weeks of treatment. Week 8 clinical response rates were significantly higher in the 8 mg QD (46.3%; P = .066), 4 mg BID (46.3%; P = .059), and 4 mg QD (43.9%; P = .095) groups vs placebo (26.8%). Week 8 rates of clinical remission were 22.0% (P = .020), 24.4% (P = .013), and 24.4% (P = .011) in the 3 ivarmacitinib treatment groups, respectively, vs 4.9% for placebo. During the initial 8-week period, treatment-emergent adverse events occurred in 43.9% to 48.8% of ivarmacitinib-treated patients and in 39.0% of the placebo group, and were predominantly mild. There were no deaths, or major adverse cardiovascular or thromboembolic events.Ivarmacitinib demonstrated clinical efficacy and was well tolerated in patients with moderate-to-severe, active, UC. Ivarmacitinib represents a promising new treatment for moderate-to-severe UC.gov number, NCT03675477.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
一个酒窝完成签到 ,获得积分10
刚刚
刚刚
彭于晏的应助被寒冷的断秋采纳,获得10
刚刚
刚刚
1秒前
嘻嘻哈哈的应助被星光采纳,获得10
1秒前
娃哈哈完成签到,获得积分10
1秒前
刘秀平完成签到,获得积分10
1秒前
研友_841KWL完成签到,获得积分10
1秒前
华仔的应助被222采纳,获得10
2秒前
yuhuzhouye完成签到,获得积分10
2秒前
成林完成签到,获得积分10
2秒前
2秒前
乐观的蜜蜂完成签到,获得积分10
2秒前
kwangil完成签到,获得积分10
2秒前
2秒前
2秒前
张羡光完成签到,获得积分10
3秒前
老迟到的翠容完成签到,获得积分10
3秒前
3Q发布了新的文献求助10
3秒前
小二郎的应助被cyn采纳,获得10
3秒前
yippee完成签到,获得积分10
4秒前
HTT完成签到,获得积分10
4秒前
4秒前
充电宝的应助被attilio采纳,获得10
4秒前
4秒前
zonker完成签到,获得积分10
4秒前
淡淡向卉完成签到,获得积分10
4秒前
落九川完成签到,获得积分10
5秒前
大罗完成签到,获得积分10
5秒前
5秒前
刘烨完成签到,获得积分10
5秒前
5秒前
健壮凤凰发布了新的文献求助10
6秒前
执着银耳汤完成签到,获得积分10
7秒前
枫枫不是峰完成签到,获得积分10
7秒前
Shawn完成签到,获得积分10
7秒前
听风发布了新的文献求助10
7秒前
核桃发布了新的文献求助10
7秒前
成就蚂蚁完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8152442
求助须知:如何正确求助?哪些是违规求助? 9549069
关于积分的说明 21690841
捐赠科研通 7740658
什么是DOI,文献DOI怎么找? 3425157
关于科研通互助平台的介绍 2550382
邀请新用户注册赠送积分活动 2468710